pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·2h ago·1 min read
save

Celcuity awaits FDA review for second factory to launch cancer drug

Celcuity has provided further details on why the commercial rollout of its recently approved cancer drug is slower than investors initially anticipated. The drugmaker said it is waiting for the FDA to review a second ...

Aug 17, 2026·read at Endpoints ↗

August 17, 2026 09:19 AM EDT PharmaManufacturing Cel­cu­ity awaits FDA re­view for sec­ond fac­to­ry to launch can­cer drug Anna Brown News Reporter Cel­cu­ity has pro­vid­ed fur­ther de­tails on why the com­mer­cial roll­out of its re­cent­ly ap­proved can­cer drug is slow­er than in­vestors ini­tial­ly an­tic­i­pat­ed. The drug­mak­er said … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
82 words · retrieved 2h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Oncology2

related stories

  • Apr 27Erasca reports RAS cancer drug data after legal threat from RevolutionEndpoints
  • Apr 27Revolution Medicines threatens to sue Erasca over patent, efficacy claimsEndpoints
  • Apr 27Lilly to buy startup Ajax in bid for a better JAK drugBioPharma Dive
  • Apr 27STAT+: Astellas retries XLMTM gene therapy after deathsSTAT
  • Apr 27Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitorEndpoints